Drug profile

The FDA adverse-event record for Butorphanol Tartrate Injection

25 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Butorphanol Tartrate Injection. See the species affected, top reactions, and outcomes below.

25
adverse-event reports
40.0%
death-coded share
Dog
most-reported species
8
Lack of efficacy - NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
25
Total Reports
10
Deaths Reported
40.0%
Death Rate

Active Ingredients

Butorphanol Tartrate Injection

Administration Routes

IntravenousIntramuscularUnknown

Species Affected

Dog 16
Horse 7
Human 1
Cat 1

Most Affected Breeds

Quarter Horse 5
Pit Bull 2
Siberian Husky 2
Shepherd Dog - German 2
Dog (unknown) 2
Schnauzer - Miniature 2
Terrier (unspecified) 1
Chihuahua 1
Mastiff 1
Great Pyrenees 1

Most Reported Reactions

Lack of efficacy - NOS 8
Death by euthanasia 6
Unrelated death 5
Ataxia 5
Seizure NOS 4
Anaphylaxis 4
Collapse (see also Cardio-vascular and Systemic disorders) 4
Pale mucous membrane 4
Death 4
Respiratory arrest 3
Cardiac arrest 2
Underdose 2

Outcome Breakdown

Recovered/Normal
10 (40.0%)
Euthanized
6 (24.0%)
Ongoing
4 (16.0%)
Died
4 (16.0%)
Outcome Unknown
1 (4.0%)

Butorphanol Tartrate Injection Adverse Event Insights

25 reports name Butorphanol Tartrate Injection; 10 recorded a death outcome (40.0% of reported events, not a population-level mortality rate). Active ingredient: Butorphanol Tartrate Injection. Administration routes: Intravenous, Intramuscular, Unknown.

By species: Dog (16 reports), Horse (7 reports), Human (1 reports). By breed: Quarter Horse (5), Pit Bull (2), Siberian Husky (2).

Leading clinical signs: Lack of efficacy - NOS (8), Death by euthanasia (6), Unrelated death (5), Ataxia (5). Outcome, 25 coded reports: Recovered/Normal leads at 40.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.